Published in J Natl Cancer Inst on May 20, 1998
Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making (2006) 11.83
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg (2004) 2.84
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res (2005) 2.44
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27
High-risk prostate cancer in the United States, 1990-2007. World J Urol (2008) 1.83
Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ (2001) 1.71
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol (2008) 1.66
Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes? BJU Int (2009) 1.58
Validation of biomarker-based risk prediction models. Clin Cancer Res (2008) 1.57
Critical review of prostate cancer predictive tools. Future Oncol (2009) 1.57
A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res (2009) 1.56
Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res (2009) 1.51
Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol (2013) 1.48
Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol (2005) 1.45
Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol (2008) 1.43
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol (2009) 1.42
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality. Br J Cancer (2015) 1.39
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res (2007) 1.38
Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol (2005) 1.37
Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest (2007) 1.35
A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol (2012) 1.32
Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol (2011) 1.32
A centralized research data repository enhances retrospective outcomes research capacity: a case report. J Am Med Inform Assoc (2013) 1.29
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.28
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol (2009) 1.27
Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.26
Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. Semin Oncol (2010) 1.25
The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol (2006) 1.20
Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol (2010) 1.19
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
The clinical features of anterior prostate cancers. BJU Int (2006) 1.12
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol (2011) 1.12
Screening for prostate cancer: an update. Can J Urol (2008) 1.11
ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia (2006) 1.10
Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer (2007) 1.09
Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int (2008) 1.08
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer (2012) 1.07
Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer (2009) 1.07
The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int (2010) 1.04
Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res (2009) 1.03
Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol (2006) 1.02
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol (2015) 1.01
Using biopsy to detect prostate cancer. Rev Urol (2008) 1.00
Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J (2012) 0.99
Effect of DNA methylation on identification of aggressive prostate cancer. Urology (2008) 0.98
Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Int J Clin Oncol (2011) 0.97
Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol (2004) 0.95
Prognostic determinants in prostate cancer. Cancer J (2011) 0.95
Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci U S A (2013) 0.95
External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Urol Oncol (2010) 0.94
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res (2009) 0.93
Role of nomograms for prostate cancer in 2007. World J Urol (2007) 0.92
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? Urology (2009) 0.90
PSA mass as a marker of prostate cancer progression after radical prostatectomy. Med Sci Monit (2011) 0.90
Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer (2005) 0.90
The role of endorectal coil MRI in preoperative staging and decision-making for the treatment of clinically localized prostate cancer. MAGMA (2008) 0.90
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys (2010) 0.90
The importance of identifying and validating prognostic factors in oncology. Semin Oncol (2010) 0.90
Predictive models for newly diagnosed prostate cancer patients. Rev Urol (2009) 0.89
The role of radical prostatectomy in high-risk prostate cancer. Prostate Int (2013) 0.89
Is there a role for chemotherapy in prostate cancer? Br J Cancer (2004) 0.89
The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. Cancer (2012) 0.89
Prostate-specific antigen screening: pro. Curr Opin Urol (2010) 0.88
An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account. PLoS One (2012) 0.88
The genomic landscape of prostate cancer. Int J Mol Sci (2013) 0.88
The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer. Asian J Androl (2014) 0.88
Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. J Urol (2011) 0.87
Prostate cancer risk assessment: choosing the sharpest tool in the shed. Cancer (2008) 0.87
FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol Oncol (2012) 0.87
Imaging biomarkers in prostate cancer: role of PET/CT and MRI. Eur J Nucl Med Mol Imaging (2015) 0.87
Benchmarks for success in focal therapy of prostate cancer: cure or control? World J Urol (2010) 0.86
Surgery for high-risk localized prostate cancer. Ther Adv Urol (2011) 0.86
Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer (2012) 0.86
Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl (2014) 0.86
Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram. Urology (2009) 0.86
Prostate volume has prognostic value only in pathologic T2 radical prostatectomy specimens. J Korean Med Sci (2011) 0.85
Elastic moduli of breast and prostate tissues under compression. Ultrason Imaging (1998) 6.90
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol (1999) 4.78
Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol (1994) 3.17
Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA (1996) 2.74
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Factors predicting recovery of erections after radical prostatectomy. J Urol (2000) 2.44
Risk factors for urinary incontinence after radical prostatectomy. J Urol (1996) 2.42
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (1995) 2.19
Erectile dysfunction in the community: a prevalence study. Med J Aust (1999) 2.03
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol (1999) 2.00
Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res (1998) 1.95
Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res (1999) 1.95
Vesicovaginal and ureterovaginal fistulas: a summary of 25 years of experience. J Urol (1980) 1.84
Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res (2000) 1.84
Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol (2000) 1.80
Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology (2001) 1.76
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology (2001) 1.65
Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol (1995) 1.63
Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol (2001) 1.63
In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate (2001) 1.58
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol (2001) 1.55
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol (1999) 1.54
Testicular metastasis as the first manifestation of colon carcinoma. J Urol (1988) 1.54
The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis (2005) 1.53
Future prospects in prostate cancer. Prostate (1999) 1.53
The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol (1994) 1.53
Possible mechanism for seeding of tumor during radical prostatectomy. J Urol (1993) 1.52
A catalog of prostate cancer nomograms. J Urol (2001) 1.51
Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer (1997) 1.50
Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology (1994) 1.48
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology (2000) 1.44
The risk of distant metastases after transurethral resection of the prostate versus needle biopsy in patients with localized prostate cancer. J Urol (1989) 1.43
Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2001) 1.42
Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology (1997) 1.41
Accuracy of fine-needle aspiration of thyroid. Arch Pathol Lab Med (2001) 1.40
A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol (1991) 1.40
Verumontanum mucosal gland hyperplasia in prostatic needle biopsy specimens. A mimic of low grade prostatic adenocarcinoma. Am J Clin Pathol (1995) 1.39
The significance of intraluminal prostatic crystalloids in benign needle biopsies. Am J Surg Pathol (1998) 1.38
15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res (2001) 1.37
Age-related radical-induced DNA damage is linked to prostate cancer. Cancer Res (2001) 1.34
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res (2000) 1.27
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther (1999) 1.26
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol (1996) 1.26
Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol (1998) 1.26
Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol (1997) 1.25
Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol (1997) 1.24
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology (1993) 1.23
The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. J Urol (1977) 1.23
The association of benign prostatic hyperplasia and cancer of the prostate. Cancer (1992) 1.22
Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res (1995) 1.22
Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol (2001) 1.22
"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology (2000) 1.20
Impact of a clinical pathway for radical retropubic prostatectomy. Urology (1998) 1.20
NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park) (2000) 1.19
Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique. Cancer (1977) 1.18
Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol (1994) 1.18
The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer (1994) 1.18
Testicular microlithiasis as a predictor of intratubular germ cell neoplasia. Urology (1996) 1.17
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer (2010) 1.16
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol (2001) 1.15
Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst (1997) 1.14
Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer (2001) 1.14
A simple ileal substitute bladder after radical cystectomy: experience with a modification of the Studer pouch. J Urol (1995) 1.14
Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene (2000) 1.13
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer (1998) 1.13
Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol (1997) 1.11
Efficacy of antimicrobial-impregnated bladder catheters in reducing catheter-associated bacteriuria: a prospective, randomized, multicenter clinical trial. Urology (1999) 1.10
Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol (2001) 1.10
Screening for prostate cancer: an analysis of the early experience. CA Cancer J Clin (1995) 1.09
Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia (2001) 1.08